CRM concentration — ~11% of net worth in a single stock. Down ~43% from late 2024 peak (~$725K → ~$410K). USD-denominated. Monitor for cross-FY staggered trim opportunities. At 19% marginal rate, effective CGT ~9.5%.
🔴
High Severity
SMSF phase unconfirmed — all CGT analysis is provisional until Peppernell confirms pension vs accumulation. Pension phase = 0% CGT; accumulation = 10% after 12-month discount. Action required before any SMSF sale.
🟡
Medium Severity
HUBS position approximately −70% underwater in SMSF on Jun 2024 tranche. Decision pending: hold for recovery or crystallise loss to offset gains within SMSF. Confirm SMSF phase first.
🟡
Medium Severity
Sequence of returns risk — no salary income, drawdown active. A major market correction in the next 2–3 years is the highest single-impact risk scenario. Review defensive cash buffer vs monthly burn ($7,877).